Amivantamab | Anti-EGFR/MET | Therapeutic Bispecific Antibody

Aliquoted from the original drug | Now available for research use

Aliquots of the reference drug Amivantamab are now available as research consumables.

Amivantamab drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed biosimilar drug.

Not looking for Amivantamab Reference drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Rybrevant® / Amivantamab Reference Product

Drug nameRybrevant®
INNAmivantamab
API typeBispecific antibody
Pharmacotherapeutic group
Monoclonal antibodies and antibody-drug conjugates
ATC code
L01FX18
Target of antibody
EGFR, MET
General function
Short descriptionAmivantamab is a fully-human Immunoglobulin G1 (IgG1)-based bispecific antibody directed against the epidermal growth factor (EGF) and mesenchymal-epidermal transition (MET) receptors, produced by a mammalian cell line (Chinese Hamster Ovary [CHO]) using recombinant DNA technology.
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Amivantamab is a low-fucose, fully-human IgG1-based EGFR-MET bispecific antibody with immune cell-directing activity that targets tumours with activating EGFR Exon 20 insertion mutations.
Amivantamab binds to the extracellular domains of EGFR and MET. Amivantamab disrupts EGFR and MET signalling functions through blocking ligand binding and enhancing degradation of EGFR and MET, thereby preventing tumour growth and progression. The presence of EGFR and MET on the surface of tumour cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Amivantamab decreased serum albumin concentration, a pharmacodynamic effect of MET inhibition; thereafter, albumin concentration stabilised for the remainder of amivantamab treatment.
Original license holder
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium
Marketing authorisation numbers
EU/1/21/1594/001
Marketing authorisation holder
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium
Name of the manufacturer of the biological active substance
Janssen Sciences Ireland UC
Barnahely
Ringaskiddy, Co. Cork
Ireland
Name and address of the manufacturer(s) responsible for batch releaseJanssen Biologics B.V.
Einsteinweg 101
2333 CB Leiden
The Netherlands
Max shelf life
24 months
Storage conditions
2°C – 8°C
List of excipients
Ethylenediaminetetraacetic acid (EDTA) disodium salt dihydrate
L-Histidine
L-Histidine hydrochloride monohydrate
L-Methionine
Polysorbate 80 (E433)
Sucrose
Water for injections

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

we are recruiting